Status:
COMPLETED
Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Adults
Lead Sponsor:
BeiGene
Conditions:
Tumor
Eligibility:
MALE
18-55 years
Phase:
PHASE1
Brief Summary
The primary objective of the study was to investigate the relative bioavailability and pharmacokinetics (PK) of sitravatinib free base and malate salt capsule formulations following oral administratio...
Eligibility Criteria
Inclusion
- Key
- Body mass index between 18.0 and 32.0 kg/m2, inclusive.
- In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, vital sign measurements, and clinical laboratory evaluations at Screening and/or Check-in as assessed by the Investigator (or designee).
- Able to swallow multiple capsules.
- Key
Exclusion
- History of stomach or intestinal surgery or resection
- Have previously completed or withdrawn from this study or any other study investigating sitravatinib and have previously received the investigational product.
- Participants who, in the opinion of the Investigator (or designee), should not participate in this study.
- NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Key Trial Info
Start Date :
July 23 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 9 2020
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT04472650
Start Date
July 23 2020
End Date
November 9 2020
Last Update
October 26 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Linear Clinical Research
Nedlands, Western Australia, Australia, 6009